Xeris Biopharma(XERS)

Search documents
Xeris Biopharma(XERS) - 2025 Q1 - Quarterly Results
2025-05-08 11:22
Exhibit 99.1 XERIS BIOPHARMA REPORTS RECORD FIRST QUARTER 2025 FINANCIAL RESULTS Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3 in New York City rd Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO, IL (BUSINESS WIRE); May 8, 2025 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical compan ...
Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings
Seeking Alpha· 2025-05-07 15:51
Group 1 - The article discusses the potential for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) to make significant upward movements in its stock price, indicating a positive outlook for the company [1] - The author has a long position in XERS shares, suggesting confidence in the company's future performance [2] - The author emphasizes a focus on innovative companies in the biotech sector that are developing breakthrough therapies and pharmaceuticals, which aligns with Xeris Biopharma's business model [1]
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
ZACKS· 2025-03-20 15:15
Company Overview - Xeris Biopharma (XERS) shares increased by 5.6% to $5.51 in the last trading session, with a notable trading volume, contributing to a total gain of 34.9% over the past four weeks [1][2] Recent Developments - The FDA approved Xeris' supplemental new drug application for Gvoke VialDx, which is intended to temporarily inhibit gastrointestinal movement during radiologic procedures in adults [2] - Xeris entered a partnership with American Regent to commercialize Gvoke VialDx in the United States, which has likely contributed to the recent optimism and share price increase [2] Financial Expectations - Xeris is projected to report a quarterly loss of $0.07 per share, reflecting a year-over-year improvement of 50% [3] - Expected revenues for the upcoming quarter are $57.75 million, representing a 42.1% increase compared to the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for Xeris has been revised 10% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting favorable market sentiment [4] Industry Context - Xeris Biopharma is part of the Zacks Medical - Drugs industry, where another company, Aurinia Pharmaceuticals (AUPH), saw a 1.7% increase in its last trading session and has returned 3% over the past month [4] - Aurinia's consensus EPS estimate has decreased by 17.5% over the past month, although it reflects a significant year-over-year change of 400% [5]
Xeris Biopharma(XERS) - 2024 Q4 - Annual Report
2025-03-06 21:07
Financial Performance - Xeris Biopharma Holdings, Inc. reported total revenue of $203.07 million for the year ended December 31, 2024, an increase of 24% compared to $163.91 million in 2023 [521]. - Product revenue, net for 2024 was $196.64 million, up 28% from $153.36 million in 2023 [521]. - The company incurred a net loss of $54.84 million in 2024, compared to a net loss of $62.26 million in 2023, reflecting a 12% improvement [521]. - Total costs and expenses increased to $236.72 million in 2024, up from $207.92 million in 2023, primarily driven by higher selling, general, and administrative expenses [521]. - The company reported a net loss of $54.8 million for the year ended December 31, 2024, compared to a net loss of $62.3 million in 2023 and $94.7 million in 2022, indicating a 12% improvement year-over-year [527]. Cash Flow and Liquidity - Net cash used in operating activities decreased to $37.0 million for the year ended December 31, 2024, from $47.0 million in 2023, primarily due to reduced working capital usage [462]. - Cash and cash equivalents as of December 31, 2024, were $71.62 million, an increase from $67.45 million in 2023 [518]. - The company had cash, cash equivalents, and restricted cash of $75.7 million at the end of 2024, up from $71.7 million in 2023 [529]. - The company expects to continue incurring net losses for at least the next 12 months, but believes current cash resources are sufficient to sustain operations during this period [535]. Debt and Financing - Long-term debt, net of current portion, rose to $217.01 million in 2024, compared to $190.93 million in 2023 [518]. - Total debt increased to $232,108,000 as of December 31, 2024, compared to $190,932,000 in 2023, reflecting a growth of 21.5% [608]. - The Amended and Restated Credit Agreement provided for $200 million in term loans, with an effective interest rate of approximately 11.4% [625]. - The company may finance operations through equity or debt financing, but there is no assurance that such funding will be available on acceptable terms, which could negatively impact financial condition and business strategies [536]. Revenue Recognition and Accounting Policies - The company recognizes revenue when customers obtain control of promised goods, with revenues recorded at the net product sales price after accounting for various allowances [471]. - The company applies significant judgments and estimates in determining allowances for patient copay assistance, commercial rebates, and government rebates, impacting reported revenues [471]. - If the company were to increase or decrease the returns reserve rate by 1%, it would have a $1.8 million impact on revenue for the year ended December 31, 2024 [552]. - The company offers savings programs to commercially insured patients, which are recorded as a reduction of product revenue [546]. Assets and Inventory - The company's total assets slightly increased to $323.06 million in 2024 from $322.60 million in 2023 [518]. - Total inventory as of December 31, 2024, was $48.18 million, compared to $38.84 million in 2023, reflecting a 24% increase [603]. - Inventory reserves increased to $7.7 million at December 31, 2024, from $2.4 million in 2023 [603]. Stock-Based Compensation - Stock-based compensation expenses increased to $18.4 million in 2024 from $10.7 million in 2023, reflecting higher employee incentives [527]. - The total fair value of RSUs vested during 2024 was $10.7 million, compared to $2.8 million in 2023 [656]. - The company recognized total stock-based compensation expense of $18.4 million in 2024, significantly higher than $10.7 million in 2023 [657]. Market Risks - The company is subject to market risks, including interest rate and foreign currency exchange rate fluctuations, but net foreign currency gains and losses did not materially affect operations for the year ended December 31, 2024 [480]. - A hypothetical one-percentage point increase or decrease in interest rates would impact interest income by approximately $0.8 million annually based on cash and investments outstanding as of December 31, 2024 [481]. Internal Controls and Compliance - The company maintained effective internal control over financial reporting as of December 31, 2024, according to the auditor's opinion [505]. - The company adopted several new accounting standards, including ASU 2023-03, with no material impact on financial statements [586].
Xeris Biopharma(XERS) - 2024 Q4 - Earnings Call Transcript
2025-03-06 20:35
Xeris Biopharma Holdings (XERS) Q4 2024 Earnings Call March 06, 2025 04:35 PM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate CommunicationsJohn Shannon - CEOSteve Pieper - Chief Financial OfficerGlen Santangelo - Managing DirectorMazahir Alimohamed - Biotech Equity Research Associate Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareOren Livnat - MD - Senior Healthcare AnalystDavid Amsellem - Sr. Research AnalystLelan ...
Xeris Biopharma(XERS) - 2024 Q4 - Earnings Call Transcript
2025-03-06 15:52
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pieper - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies David Amsellem - Piper Sandler Leland Gershell - Oppenheimer Mazahir Alimohamed - Leerink Partners Operator Good morning, and welcome to the Xeris Biopharma Fourth Quarter and Fu ...
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings
ZACKS· 2025-03-06 15:30
Group 1 - Xeris Biopharma reported $60.1 million in revenue for Q4 2024, a year-over-year increase of 35.4% [1] - The EPS for the same period was -$0.03, improving from -$0.10 a year ago, with a surprise of +57.14% compared to the consensus estimate of -$0.07 [1][3] - The revenue reported was a slight miss of -0.81% against the Zacks Consensus Estimate of $60.59 million [1] Group 2 - Key product revenues included Gvoke at $23.26 million, Keveyis at $11.12 million, and Recorlev at $22.61 million, with Recorlev significantly outperforming its estimate of $11.19 million [4] - Royalty, contract, and other revenues were reported at $3.10 million, exceeding the average estimate of $1.30 million [4] - Overall product revenue, net, was $57 million, slightly above the estimated $56.26 million [4] Group 3 - Xeris Biopharma's shares returned +2.7% over the past month, contrasting with the Zacks S&P 500 composite's -3.5% change [3] - The company currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near term [3]
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates
ZACKS· 2025-03-06 14:15
Group 1 - Xeris Biopharma reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and an improvement from a loss of $0.10 per share a year ago, representing an earnings surprise of 57.14% [1] - The company posted revenues of $60.1 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.81%, but showing an increase from year-ago revenues of $44.39 million [2] - Xeris Biopharma shares have increased by approximately 11.2% since the beginning of the year, contrasting with a decline of -0.7% in the S&P 500 [3] Group 2 - The earnings outlook for Xeris Biopharma is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for Xeris Biopharma is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $54.1 million, and -$0.22 on revenues of $240.93 million for the current fiscal year [7] Group 3 - The Medical - Drugs industry, to which Xeris Biopharma belongs, is currently ranked in the bottom 46% of over 250 Zacks industries, which may impact stock performance [8] - VAXART, INC., another company in the same industry, is expected to report a quarterly loss of $0.10 per share, reflecting a year-over-year change of +16.7%, with revenues projected at $31.17 million, up 859.1% from the year-ago quarter [9]
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
ZACKS· 2025-02-26 16:05
Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Xeris Biopharma, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Financial Expectations - Xeris Biopharma is expected to report a quarterly loss of $0.07 per share, reflecting a year-over-year change of +30% [3]. - Revenues are projected to be $60.59 million, representing a 36.5% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate for Xeris Biopharma is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.78%, suggesting a bullish outlook from analysts [10]. Earnings Surprise Prediction - A positive Earnings ESP reading is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [8][11]. - Xeris Biopharma's current Zacks Rank of 2 enhances the likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Xeris Biopharma was expected to post a loss of $0.09 per share but actually reported a loss of $0.06, achieving a surprise of +33.33% [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13]. Industry Context - Esperion Therapeutics, another player in the Zacks Medical - Drugs industry, is expected to report a loss of $0.14 per share, with a year-over-year change of +72% and projected revenues of $70.01 million, up 117.1% from the previous year [17]. - Esperion's consensus EPS estimate has remained unchanged, but a lower Most Accurate Estimate has resulted in an Earnings ESP of -8.70%, combined with a Zacks Rank of 4 (Sell), making it difficult to predict an earnings beat [18].
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
Prnewswire· 2025-01-21 14:00
Core Viewpoint - The American Diabetes Association (ADA) and Xeris Pharmaceuticals have formed a multi-year strategic partnership to promote the importance of glucagon prescriptions for individuals with diabetes on blood glucose-lowering medications, particularly those at risk of severe hypoglycemia [1][2][3] Group 1: Partnership Objectives - The partnership aims to increase awareness and education regarding the necessity of having glucagon, preferably in a ready-to-use formulation, for individuals with diabetes treated with insulin or insulin secretagogues [1][2] - The ADA and Xeris will develop educational materials and training resources for healthcare professionals and individuals living with diabetes, alongside a national awareness campaign [2] Group 2: Health Statistics and Risks - It is estimated that up to 46% of individuals with type 1 diabetes and 21% of those with type 2 diabetes using insulin experience at least one severe hypoglycemia event annually [1] - Severe hypoglycemia is responsible for over 202,000 emergency department visits each year, with approximately 25% of these cases resulting in hospital admissions [1] Group 3: Company Profiles - The ADA is a leading health organization focused on ending diabetes and supporting individuals living with the condition, with 136 million Americans affected by diabetes or prediabetes [4] - Xeris Pharmaceuticals is a biopharmaceutical company that develops innovative products, including Gvoke®, a ready-to-use liquid glucagon for treating severe hypoglycemia [5]